An Open Label Dose Escalation and Pharmacokinetic Phase I Study With Pazopanib in Combination With Cisplatin (CDDP) Every Three Weeks in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2016
At a glance
- Drugs Pazopanib (Primary) ; Cisplatin
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms PACIFIK
- 16 Nov 2014 Status changed from recruiting to completed, as reported by ClinicalTrials.gov record.
- 15 Jan 2014 Planned End Date changed from 1 Dec 2013 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
- 25 Jul 2010 New trial record